TG4010 A therapeutic vaccine against MUC1 expressing tumors

被引：39
|
作者：
Limacher, Jean-Marc [1 ]
Quoix, Elisabeth [2 ]
机构：
[1] Transgene SA, Illkirch Graffenstaden, France
[2] Nouvel Hop Civil, Hop Univ Strasbourg, Strasbourg, France
来源：
ONCOIMMUNOLOGY | 2012年 / 1卷 / 05期
关键词：
non-small cell lung cancer; cancer vaccine; TG4010; biomarker; CELL LUNG-CANCER; IMMUNOTHERAPY; CHEMOTHERAPY; MVA-MUC1-IL2;
D O I：
10.4161/onci.19863
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TG4010 is a therapeutic cancer vaccine based on a viral vector, a modified vaccinia of Ankara (MVA), expressing MUC1 as well as interleukine 2. Today the clinical development is focused on advanced non-small cell lung cancer in combination with first line chemotherapy. Potential biomarkers predictive of activity have been identified.
引用
收藏
页码：791 / 792
页数：2
相关论文
共 50 条
  • [41] Immune recognition of tumor-associated mucin MUC1 is achieved by a fully synthetic aberrantly glycosylated MUC1 tripartite vaccine
    Lakshminarayanan, Vani
    Thompson, Pamela
    Wolfert, Margreet A.
    Buskas, Therese
    Bradley, Judy M.
    Pathangey, Latha B.
    Madsen, Cathy S.
    Cohen, Peter A.
    Gendler, Sandra J.
    Boons, Geert-Jan
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2012, 109 (01) : 261 - 266
  • [42] MUC1 and metastatic cancer Expression, function and therapeutic targeting
    Horm, Teresa M.
    Schroeder, Joyce A.
    CELL ADHESION & MIGRATION, 2013, 7 (02) : 187 - 198
  • [43] MUC1 is a promising therapeutic target for prostate cancer therapy
    Li, Y.
    Cozzi, P. J.
    CURRENT CANCER DRUG TARGETS, 2007, 7 (03) : 259 - 271
  • [44] Up-regulation of MUC1 in mammary tumors generated in a double-transgenic mouse expressing human MUC1 cDNA, under the control of 1.4-kb 5′ MUC1 promoter sequence and the middle T oncogene, expressed from the MMTV promoter
    Graham, RA
    Morris, JR
    Cohen, EP
    Taylor-Papadimitriou, J
    INTERNATIONAL JOURNAL OF CANCER, 2001, 92 (03) : 382 - 387
  • [45] Induction of protective and therapeutic anti-pancreatic cancer immunity using a reconstructed MUC1 DNA vaccine
    Yefei Rong
    Dayong Jin
    Wenchuan Wu
    Wenhui Lou
    Danshong Wang
    Tiantao Kuang
    Xiaoling Ni
    Xinyu Qin
    BMC Cancer, 9
  • [46] The Tat-conjugated N-terminal region of mucin antigen 1 (MUC1) induces protective immunity against MUC1-expressing tumours
    Yang, H.
    Cho, N. -H.
    Seong, S. -Y.
    CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2009, 158 (02): : 174 - 185
  • [47] Induction of protective and therapeutic anti-pancreatic cancer immunity using a reconstructed MUC1 DNA vaccine
    Rong, Yefei
    Jin, Dayong
    Wu, Wenchuan
    Lou, Wenhui
    Wang, Danshong
    Kuang, Tiantao
    Ni, Xiaoling
    Qin, Xinyu
    BMC CANCER, 2009, 9
  • [48] Dendritic cell vaccine immunotherapy of cancer targeting MUC1 mucin
    Kontani, K
    Taguchi, O
    Ozaki, Y
    Hanaoka, J
    Sawai, S
    Inoue, S
    Abe, H
    Hanasawa, K
    Fujino, S
    INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 2003, 12 (04) : 493 - 502
  • [49] A phase II study of the cancer vaccine TG4010 alone and in combination with cytokines in patients with metastatic renal clear-cell carcinoma: clinical and immunological findings
    Oudard, Stephane
    Rixe, Olivier
    Beuselinck, Benoit
    Linassier, Claude
    Banu, Eugeniu
    Machiels, Jean-Pascal
    Baudard, Marion
    Ringeisen, Francois
    Velu, Thierry
    Lefrere-Belda, Marie-Aude
    Limacher, Jean-Marc
    Fridman, W. H.
    Azizi, Michel
    Acres, Bruce
    Tartour, Eric
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2011, 60 (02) : 261 - 271
  • [50] MAb RR-B7 against MUC1
    Rahbarizadeh, F
    Rasaee, MJ
    HYBRIDOMA AND HYBRIDOMICS, 2004, 23 (01): : 79 - 79
12345